Overview

2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and tolerability of specific subcutaneous immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense) in subjects with rhinoconjunctivitis caused by grass pollen with/without controlled asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Allergopharma GmbH & Co. KG